Immuno-Oncology / Checkpoint

Akeso has secured Phase I clinical trial clearance in China for AK158D1, a bispecific antibody drug conjugate targeting EGFR and TROP2 in advanced solid tumors. The clearance puts fresh attention on the company's pipeline as it pushes deeper into IO2.0 and ADC2.0. Akeso's shares recently traded at HK$90.5, up 3.37% over 90 days but down 20.12% year to date, against a consensus analyst price target of HK$158.28, with the most bullish target at HK$226.04 and the most bearish at HK$125.08. The company remains exposed to execution setbacks given its reliance on a handful of key drugs and a current net loss of CN¥967.2 million.

Merck received a positive opinion from the European Medicines Agency's CHMP for KEYTRUDA plus Padcev in muscle-invasive bladder cancer. The CHMP backed the combination as perioperative therapy for adults with resectable muscle-invasive bladder cancer in the European Union. If endorsed by the European Commission, the regimen would be the first PD-1 inhibitor plus antibody-drug conjugate option for this setting in Europe. The addressable group in Europe is relatively concentrated but clinically high need, with bladder cancer cases estimated at about 224,700 in 2022, roughly 25% of them classified as muscle invasive. The key near-term marker is the European Commission ruling expected by the fourth quarter of 2026, since the CHMP only issues recommendations.

Merck shares rose approximately 1.0% to $146.39 Thursday as the pharmaceutical and oncology heavyweight entered the next era of commercial space research, with its blockbuster cancer drug Keytruda already benefiting from work conducted in orbit. Research aboard the International Space Station helped scientists better understand protein crystallization, contributing to the development of a faster subcutaneous formulation of Keytruda, and NASA's research overview explains that microgravity can produce larger and more orderly protein crystals, potentially giving researchers clearer structural information. As the ISS approaches retirement, commercial stations could offer drugmakers dedicated equipment and more predictable research schedules, although regulators still lack a purpose-built approval framework for medicines manufactured in space. The commercial stakes are already enormous: Keytruda generated about $8.37 billion of Merck's latest $16.61 billion quarter, roughly half of total revenue, while the subcutaneous version contributed $463 million, or around 5.5% of Keytruda sales. At $146.39, Merck trades 21.85% above its GF Value estimate of $120.14, signaling that investors are already paying a meaningful premium to the model's estimate of fair value.

Moderna and Merck reported positive results from the late-stage INTerpath-001 study of intismeran autogene (V940/mRNA-4157) in combination with Keytruda in patients with high-risk Stage IIB-IV melanoma whose tumors had been removed through surgery. The study met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival, with the companies stating the improvements were statistically significant and clinically meaningful, though no numerical data were disclosed. INTerpath-001 marks the first positive phase III readout for an individualized neoantigen therapy and an mRNA-based cancer therapy, and five-year follow-up from the phase IIb KEYNOTE-942 study showed the combination reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% versus Keytruda alone. Moderna and Merck are evaluating intismeran across nine phase II and phase III studies spanning multiple tumor types, including non-small cell lung cancer, bladder cancer and renal cell carcinoma, while Moderna's broader pipeline includes separate mRNA-based cancer antigen therapies, a T-cell engager and a cell-therapy enhancer. Moderna shares have skyrocketed nearly 400% year to date, outperforming the industry's 7% growth, and the stock trades at 23.44 times forward 12-month sales versus the industry average of 1.90 times.

Johnson & Johnson announced new Phase 2b COPERNICUS study results showing low rates of treatment-related events for subcutaneous RYBREVANT FASPRO plus LAZCLUZE with prophylactic strategies in previously untreated advanced EGFR-mutated non-small cell lung cancer. In the analysis of 214 U.S. patients at a median follow-up of 8.3 months, rash was reported in 25 percent of patients, while administration-related reactions and venous thromboembolism were each reported in three percent, and only eight percent discontinued treatment due to adverse events. These rates are numerically lower than those seen with intravenous RYBREVANT plus LAZCLUZE in the Phase 3 MARIPOSA study, where rash, administration-related reactions and venous thromboembolism during the first four months were reported in 55 percent, 55 percent and 23 percent of patients, respectively. COPERNICUS is one of the largest global studies in EGFR-mutated NSCLC, with a target enrollment of 300 previously untreated patients; the reported population had a median age of 67 years, with 27 percent Asian, 10 percent African American and 10 percent Hispanic or Latino. The data were presented at the IASLC 2026 World Conference on Lung Cancer in Seoul.

Merck & Co. reported second-quarter worldwide sales of $16.6 billion, with its oncology franchise led by intravenous Keytruda and the subcutaneous formulation Keytruda QLEX generating $8.4 billion in quarterly revenue. The pulmonary arterial hypertension treatment Winrevair surged 75% to reach $588 million, and management raised its full-year 2026 sales guidance to a range between $66.3 billion and $67.3 billion. The company faces the loss of exclusivity for Keytruda toward the end of 2028, pushing it to fund and acquire new pipeline assets, including a personalized mRNA cancer vaccine collaboration with Moderna. According to Insider Monkey's database, 101 hedge funds held a stake in the company during the second quarter, up from 98 in the prior quarter, while short interest sits at just 0.99% of the float. Fisher Asset Management maintained the top position with 38.5 million shares, increasing its holdings by 46%.

Amgen and AstraZeneca reported that combining Amgen's Imdelltra with AstraZeneca's Imfinzi significantly improved overall survival in a late-stage trial of patients with extensive-stage small-cell lung cancer. The combination was tested as a maintenance treatment against Imfinzi alone in patients whose disease had not progressed after initial therapy, and it also improved progression-free survival and response rates with no new safety concerns. For Amgen, the result matters because Imdelltra generated $513 million in sales last year and already holds full U.S. approval for extensive-stage small-cell lung cancer, while cancer therapies account for roughly 23% of the company's sales. For AstraZeneca, the data reinforce its Imfinzi franchise and offer evidence of pipeline depth after recent setbacks including the discontinuation of its volrustomig lung-cancer trial, as the company targets $80 billion in annual revenue by 2030. Analysts caution that the trial strengthens both companies' long-term oncology franchises rather than immediately transforming earnings, since Amgen would need substantial uptake in the maintenance setting and AstraZeneca still faces broader pipeline concerns.

AstraZeneca's late-stage trial found that combining Tagrisso with Orpathys significantly extended progression-free survival compared with Tagrisso alone in previously untreated patients with EGFR-mutated advanced non-small cell lung cancer whose tumors expressed moderate to high levels of the MET protein. Lead principal investigator Yi-Long Wu said the observed clinical benefit could reshape initial treatment for this distinct patient population. AstraZeneca also reported encouraging overall-survival benefits as a secondary objective, though the company did not establish that the result was statistically significant. The combination's safety profile was consistent with the known profiles of Tagrisso and Orpathys, with no new safety findings, but detailed adverse-event results have not yet been presented. The results could support AstraZeneca's target of $80 billion in total annual sales by 2030, with cancer medicines contributing nearly half of company sales and Tagrisso among its leading products; Orpathys is being developed with Hutchmed. A successful late-stage study does not by itself establish regulatory approval or commercial adoption, and much depends on the companies' application plans, regulatory timelines, and expected sales.

The health-care sector was on track for its strongest week since June 26, with the Health Care index rising more than 4% in the five trading days leading up to August 21, compared to a 7.9% increase in late June. The spark was a single piece of clinical trial news: Moderna and Merck announced on August 19 that their tailored mRNA cancer treatment was successful in a late-stage trial, significantly improving recurrence-free survival and distant metastasis-free survival compared with Keytruda alone in a study of over 1,100 patients. The Phase 3 trial, dubbed INTerpath-001, tested an individualized cancer vaccine called intismeran autogene in combination with Merck's blockbuster immunotherapy Keytruda in patients with completely resected stage IIB-IV melanoma. The trial achieved both its primary goals, recurrence-free survival, and a critical secondary target, distant metastasis-free survival, when compared to Keytruda alone. The companies stated that no new safety signals arose throughout the trial, and that the results expanded on previous Phase 2b data showing that the combination reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% compared to Keytruda alone. Personalized neoantigen vaccines have been considered as a cancer treatment concept for many years, but this is the first randomized Phase 3 experiment to definitely confirm their effectiveness. Moderna shares rose around 177% on the day of the news, adding approximately $45 billion to the company's market capitalization, while Merck posted a more modest but still significant 12% single-day rise. More broadly, roughly two-thirds of health-care stocks in a broad screen of over 100 names were higher on the week, with pharmaceutical and life-sciences names such as IQVIA, Danaher, and Thermo Fisher among the sector's other leaders, indicating that the rally is the result of renewed enthusiasm for the industry instead of a single-stock event.

Moderna and Merck announced that their individualized mRNA neoantigen therapy paired with Keytruda hit its primary endpoint in the Phase 3 INTerpath-001 melanoma trial, triggering a nearly 177% rally in Moderna, a gain of over 12% for Merck, and a jump of more than 4% in the SPDR S&P Biotech ETF to its highest level since February 2021. The trial win lifted gene-editing and AI drug discovery names broadly, with Prime Medicine, Intellia, CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics rallying alongside the sector, and the iShares Genomics Immunology and Healthcare ETF jumping 13.53% in a single session on 2.8 times average volume. Analysts have turned more constructive on biotech ETFs, citing valuation, technical momentum, and M&A potential, with Bank of America's Research Investment Committee noting biotech has generated returns of roughly 10% or more since June and is being flagged as a diversification play away from crowded technology positioning. Potential targets for M&A include Revolution Medicines, IDEAYA Biosciences, Arcus Biosciences, and Iovance Biotherapeutics, while risks include macro shocks and the structural volatility of small-cap clinical-stage names.

Moderna and Merck announced that their personalized mRNA cancer therapy intismeran autogene, combined with Keytruda, met its primary endpoint of recurrence-free survival in a late-stage melanoma study. The INTerpath-001 trial also met the secondary goal of distant metastasis-free survival in patients with high-risk Stage IIB-IV melanoma after surgery. The companies are testing intismeran in nine additional phase II and III studies across lung, bladder, and kidney cancers. Moderna sees the result as validation of its mRNA platform beyond infectious-disease vaccines, though it still faces competition from BioNTech and others, and its stock trades at a premium with a Zacks Rank of 3, or Hold.

GeoVax Labs highlighted positive Phase 3 results from Moderna and Merck's intismeran autogene plus KEYTRUDA combination in resected high-risk melanoma, calling it clinical validation for its planned Gedeptin plus KEYTRUDA study. The INTerpath-001 trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival, showing statistically significant and clinically meaningful improvements over KEYTRUDA alone. GeoVax believes the success reinforces the broader paradigm of combining checkpoint inhibition with therapies that generate or enhance anti-tumor immune responses, directly supporting its Gedeptin development strategy. Gedeptin uses a gene-directed enzyme prodrug therapy to destroy tumors locally and prime the tumor microenvironment, and published preclinical research showed enhanced anti-tumor immune responses when combined with anti-PD-1 therapy. GeoVax is preparing the next phase of Gedeptin clinical development in combination with KEYTRUDA for head and neck squamous cell carcinoma.

GSK said the FDA has accepted its supplemental Biologics License Application for Jemperli, also known as dostarlimab, for priority review in previously untreated stage II/III dMMR/MSI-H locally advanced rectal cancer. The FDA has set a PDUFA action date of February 2027. The application is also eligible for expedited review under the National Priority Voucher program, which could lead to an earlier FDA decision. The application is based on positive data from the registrational phase II, single-arm AZUR-1 trial, which met its primary objective by demonstrating a meaningful and sustained clinical complete response rate for 12 months with no detectable signs of cancer for at least one year.

The Phillip World Innovation Fund, or PWIN, and the Phillip World Innovation Retirement Mutual Fund, or PWINRMF, have received a positive boost from the global rise in healthcare stocks, one of the three core investment themes the funds emphasize, alongside information technology, semiconductors, AI and data centers, and clean energy infrastructure. The S&P 500 Healthcare Index has risen 10.8% since the outbreak of conflict in the Middle East, calculated from the closing price on March 2, 2026, compared with the closing price on August 19, 2026, according to Bloomberg data. A specific positive factor came from late-stage trial results in patients with melanoma skin cancer, indicating that the use of Moderna's mRNA vaccine in combination with Merck's Keytruda produced positive outcomes. This sent Moderna's share price soaring by as much as 176% and lifted Merck's shares by 12% on August 19 alone. Other healthcare stocks such as Eli Lilly, Novartis, and Pfizer also saw significant gains.

AbbVie announced it will present new data across its lung cancer pipeline at the 2026 World Conference on Lung Cancer, including Phase 1b results for its PD-1/VEGF bispecific antibody ABBV-1480 in frontline non-small cell lung cancer. At the 10 mg/kg dose, the objective response rate was 90.0% in squamous NSCLC and 75.9% in non-squamous NSCLC, with no grade 3 or higher hemorrhages observed. The company will also share updates on telisotuzumab adizutecan and ABBV-706, an investigational SEZ6-targeted antibody-drug conjugate that previously demonstrated an 82% objective response rate in relapsed/refractory small cell lung cancer. AbbVie said the presentations reflect its strategy to build a lung cancer portfolio spanning next-generation immunotherapies, targeted ADCs, and potential novel combinations.

U.S. biopharmaceutical giant Moderna announced on the 19th that a messenger RNA cancer vaccine being co-developed with pharmaceutical giant Merck showed efficacy in reducing the risk of melanoma recurrence and metastasis in a late-stage clinical trial. The trial combined the vaccine with Merck's immunotherapy drug Keytruda and showed it was more effective than Keytruda alone. This is the first time an mRNA cancer vaccine has shown positive results in a late-stage trial, sending Moderna's stock up 177 percent and Merck's up about 12 percent. Moderna President Stephen Hoge noted that because the vaccine has received breakthrough therapy designation from regulators, it could become available as early as 2027.

Moderna shares more than doubled on Wednesday, adding about $30 billion to its market value, after promising late-stage data on its personalized mRNA cancer therapy developed with Merck sent investors piling into the stock. The vaccine, intismeran, reduced the risk of recurrence and spread of skin cancer when combined with Merck's blockbuster immunotherapy drug Keytruda in a late-stage trial. Leerink Partners analysts now expect about $1.4 billion sales potential for the therapy by 2032, up from their previous projection of up to $1.2 billion. Short sellers faced record one-day losses, with short interest at 13.5% of the free float, according to ORTEX. The Nasdaq biotech index rose 4.4% to a fresh record high, while BioNTech climbed 20% and Novavax rose 6%.